Why Has Glenmark Launched Lacosamide Injection In The US?
Glenmark Pharmaceuticals has expanded its presence in the United States pharmaceutical market with the launch of Lacosamide Injection USP, a generic version of UCB’s Vimpat Injection used for the treatment of epilepsy.
The product has been introduced through the company’s US subsidiary and is available in a 200 mg/20 mL single-dose vial format. According to the company, the newly launched injection is both bioequivalent and therapeutically equivalent to the reference-listed drug Vimpat Injection, allowing it to serve as a lower-cost alternative for patients and healthcare providers.
The launch forms part of Glenmark’s broader strategy to strengthen its portfolio of complex and differentiated products in the highly competitive US generics market.
What Is Lacosamide Injection Used For?
Lacosamide is an anti-epileptic medication primarily prescribed for the treatment of seizures associated with epilepsy.
The injectable formulation is often used in hospital settings or situations where oral administration may not be suitable for patients. By offering a generic version of the therapy, Glenmark aims to improve access to treatment while helping reduce healthcare costs.
The company stated that the product meets the required standards for safety, efficacy, and quality established by US regulators.
How Large Is The Market Opportunity For Glenmark?
According to IQVIA data cited by Glenmark, the reference drug Vimpat Injection generated annual sales of approximately $15.2 million in the United States during the twelve months ended April 2026.
While the market size may appear modest compared to blockbuster pharmaceutical products, generic injectable medicines often offer attractive opportunities due to limited competition, specialized manufacturing requirements, and stable demand from healthcare institutions.
Industry analysts note that injectable generics have become an increasingly important growth segment for pharmaceutical companies seeking higher-margin products in the US market.
Why Are Injectable Generics Becoming Important?
Injectable medicines generally require more complex manufacturing capabilities and stricter quality controls than traditional oral drugs.
As a result, fewer companies compete in the segment, creating opportunities for manufacturers with established regulatory and production expertise.
The segment has become a key growth area for pharmaceutical firms looking to diversify beyond conventional tablet-based generics.
How Does This Fit Into Glenmark’s US Strategy?
Marc Kikuchi, President and Business Head, North America, said the launch reflects the company’s long-term strategy of building a broader and more differentiated product portfolio in the United States.
According to Kikuchi, Glenmark remains focused on disciplined execution while expanding its footprint across specialized pharmaceutical categories.
The company believes that introducing affordable alternatives to branded therapies can help address the needs of healthcare providers while enhancing patient access to essential treatments.
The latest launch also strengthens Glenmark’s position in the injectable medicines category, which has emerged as a major focus area for the company.
What Other Lacosamide Products Has Glenmark Introduced?
The launch marks Glenmark’s third major expansion within the Lacosamide product segment in the United States.
The company first received approval for generic Lacosamide tablets in 2022 before introducing a Lacosamide oral solution in 2024.
With the addition of the injectable version, Glenmark now offers multiple dosage formats of the epilepsy treatment, enabling it to address a wider range of patient and healthcare provider requirements.
This portfolio approach allows the company to strengthen its presence in a therapeutic category while leveraging existing regulatory approvals and commercial infrastructure.
How Is Glenmark Expanding Its Injectable Portfolio?
The Lacosamide launch is part of a broader push into injectable medicines.
During 2026, Glenmark has launched several injectable products in the US market, including Vancomycin Hydrochloride Injection, Sodium Phosphates Injection, and Potassium Phosphates Injection.
The company has increasingly focused on complex generics and hospital-administered products, segments that often offer stronger growth prospects and less pricing pressure compared to traditional generic medicines.
With 11 manufacturing facilities and commercial operations across more than 80 countries, Glenmark continues to invest in expanding its global pharmaceutical footprint.
What Does This Mean For Glenmark’s Growth Prospects?
The launch reinforces Glenmark’s strategy of targeting specialized generic opportunities in regulated markets.
While the immediate revenue contribution from Lacosamide Injection may be limited relative to the company’s overall business, the product strengthens its portfolio and enhances its competitive position in the US healthcare market.
As demand for affordable therapies continues to rise and healthcare systems seek cost-effective treatment alternatives, Glenmark’s growing injectable and complex generics portfolio could support future growth and diversification.
